Login to Your Account

Genentech Buys Tysabri Plant For $408M From Biogen Idec

By Randall Osborne

Monday, June 20, 2005
To keep pace with the roaring success of its compounds, Genentech Inc. is buying Biogen Idec Inc.'s 60-acre biologics manufacturing plant in Oceanside, Calif. - the one that had been slated to make ill-fated Tysabri - for $408 million, thus boosting Genentech's drug-making capacity by about 30 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription